Compare Capri Holdings Ltd (CPRI) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Danaher Corporation — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.64B), while Danaher Corporation trades at $217.88 (market cap $153.60B). The key difference: Danaher Corporation is far larger — about 93.7× Capri Holdings Ltd's market cap, and Danaher Corporation pays a 0.73% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Danaher Corporation for 69 Days on average.
| CPRI | DHR | |
|---|---|---|
Market Cap | $1.64B | $153.60B |
Volume | 1,891,363 | 3,974,063 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $242.05 |
52-Week Low | $12.71 | $161.91 |
Typical Hold Time | 41 Days | 69 Days |
Enterprise Value | $2.92B | $175.81B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up slightly by 0.07% today, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue declined to $4.44 billion in 2025, and net income was negative $1.18 billion, though 2026 projections show a return to profitability. The company's balance sheet shows total assets of $5.21 billion against liabilities of $4.84 billion, with a high ROE of 252.89% but modest net income margin of 4.44%.
The outlook is mixed: analyst consensus is a Buy with a $20.57 price target, implying significant upside, but recent news highlights turnaround risks and a lowered 2027 sales view. Key risks include Michael Kors brand weakness and competitive pressures in the luxury sector. Cash flow trends show consistent negative net cash flow, adding to execution concerns amid efforts to revitalize brands.
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
